Drugs / Iparolizumab-tovorilimab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07397442 Background | Mar 2026 → Dec 2027 expected | rectum adenocarcinoma | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparolizumab-tovorilimab | “Qibei'an (Iparolizumab-tovorilimab Injection):” NCT07397442 ↗ |
| Known as | Qibei'an | “Qibei'an (Iparolizumab-tovorilimab Injection):” NCT07397442 ↗ |
| Route | Intravenous | “5 mg/kg intravenous drip, administered once 2 days after radiotherapy completion” NCT07397442 ↗ |